nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—colon cancer	0.354	0.54	CbGaD
Pomalidomide—ABCB1—colon cancer	0.301	0.46	CbGaD
Pomalidomide—CYP1A2—Fluorouracil—colon cancer	0.0241	0.237	CbGbCtD
Pomalidomide—ABCB1—Irinotecan—colon cancer	0.022	0.216	CbGbCtD
Pomalidomide—ABCB1—Vincristine—colon cancer	0.0192	0.189	CbGbCtD
Pomalidomide—CYP3A4—Irinotecan—colon cancer	0.0132	0.13	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—colon cancer	0.0116	0.114	CbGbCtD
Pomalidomide—CYP3A4—Vincristine—colon cancer	0.0115	0.113	CbGbCtD
Pomalidomide—TNF—vagina—colon cancer	0.00372	0.0933	CbGeAlD
Pomalidomide—CRBN—embryo—colon cancer	0.00324	0.0814	CbGeAlD
Pomalidomide—CRBN—renal system—colon cancer	0.00245	0.0616	CbGeAlD
Pomalidomide—TNF—lymph node—colon cancer	0.0024	0.0604	CbGeAlD
Pomalidomide—Lenalidomide—PTGS2—colon cancer	0.00207	0.408	CrCbGaD
Pomalidomide—CRBN—lymphoid tissue—colon cancer	0.00204	0.0511	CbGeAlD
Pomalidomide—CRBN—digestive system—colon cancer	0.00201	0.0505	CbGeAlD
Pomalidomide—CRBN—bone marrow—colon cancer	0.00185	0.0466	CbGeAlD
Pomalidomide—CRBN—vagina—colon cancer	0.00178	0.0446	CbGeAlD
Pomalidomide—Lenalidomide—ABCB1—colon cancer	0.00176	0.347	CrCbGaD
Pomalidomide—PTGS2—endothelium—colon cancer	0.0016	0.0403	CbGeAlD
Pomalidomide—CRBN—liver—colon cancer	0.0015	0.0376	CbGeAlD
Pomalidomide—PTGS2—blood vessel—colon cancer	0.00148	0.0371	CbGeAlD
Pomalidomide—PTGS2—gall bladder—colon cancer	0.00139	0.0349	CbGeAlD
Pomalidomide—Thalidomide—PTGS2—colon cancer	0.00124	0.245	CrCbGaD
Pomalidomide—CRBN—lymph node—colon cancer	0.00115	0.0288	CbGeAlD
Pomalidomide—ABCB1—blood vessel—colon cancer	0.000915	0.023	CbGeAlD
Pomalidomide—PTGS2—embryo—colon cancer	0.000882	0.0222	CbGeAlD
Pomalidomide—CYP1A2—renal system—colon cancer	0.000806	0.0202	CbGeAlD
Pomalidomide—PTGS2—epithelium—colon cancer	0.00072	0.0181	CbGeAlD
Pomalidomide—Hyponatraemia—Irinotecan—colon cancer	0.0007	0.00439	CcSEcCtD
Pomalidomide—PTGS2—smooth muscle tissue—colon cancer	0.000694	0.0174	CbGeAlD
Pomalidomide—Urinary retention—Vincristine—colon cancer	0.00068	0.00427	CcSEcCtD
Pomalidomide—Interstitial lung disease—Methotrexate—colon cancer	0.000676	0.00424	CcSEcCtD
Pomalidomide—Bone pain—Capecitabine—colon cancer	0.000671	0.00421	CcSEcCtD
Pomalidomide—PTGS2—renal system—colon cancer	0.000668	0.0168	CbGeAlD
Pomalidomide—Dehydration—Vincristine—colon cancer	0.000665	0.00418	CcSEcCtD
Pomalidomide—CYP1A2—digestive system—colon cancer	0.000661	0.0166	CbGeAlD
Pomalidomide—Blood creatinine increased—Irinotecan—colon cancer	0.000653	0.0041	CcSEcCtD
Pomalidomide—Dehydration—Irinotecan—colon cancer	0.000648	0.00407	CcSEcCtD
Pomalidomide—Pulmonary embolism—Capecitabine—colon cancer	0.000643	0.00404	CcSEcCtD
Pomalidomide—Hypokalaemia—Irinotecan—colon cancer	0.000634	0.00398	CcSEcCtD
Pomalidomide—Muscular weakness—Vincristine—colon cancer	0.000631	0.00396	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Capecitabine—colon cancer	0.00062	0.0039	CcSEcCtD
Pomalidomide—Dry skin—Fluorouracil—colon cancer	0.000612	0.00384	CcSEcCtD
Pomalidomide—Neuropathy—Capecitabine—colon cancer	0.000603	0.00379	CcSEcCtD
Pomalidomide—Nasopharyngitis—Fluorouracil—colon cancer	0.000597	0.00375	CcSEcCtD
Pomalidomide—Muscular weakness—Fluorouracil—colon cancer	0.000589	0.0037	CcSEcCtD
Pomalidomide—Pancytopenia—Vincristine—colon cancer	0.000587	0.00369	CcSEcCtD
Pomalidomide—CYP3A4—renal system—colon cancer	0.000584	0.0147	CbGeAlD
Pomalidomide—Neutropenia—Vincristine—colon cancer	0.000578	0.00363	CcSEcCtD
Pomalidomide—Neutropenia—Irinotecan—colon cancer	0.000563	0.00354	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Irinotecan—colon cancer	0.00056	0.00352	CcSEcCtD
Pomalidomide—Weight decreased—Vincristine—colon cancer	0.00056	0.00351	CcSEcCtD
Pomalidomide—Sepsis—Capecitabine—colon cancer	0.000558	0.0035	CcSEcCtD
Pomalidomide—Pneumonia—Vincristine—colon cancer	0.000555	0.00348	CcSEcCtD
Pomalidomide—PTGS2—lymphoid tissue—colon cancer	0.000555	0.0139	CbGeAlD
Pomalidomide—Pancytopenia—Fluorouracil—colon cancer	0.000548	0.00344	CcSEcCtD
Pomalidomide—PTGS2—digestive system—colon cancer	0.000548	0.0138	CbGeAlD
Pomalidomide—ABCB1—embryo—colon cancer	0.000546	0.0137	CbGeAlD
Pomalidomide—Weight decreased—Irinotecan—colon cancer	0.000545	0.00342	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Vincristine—colon cancer	0.000541	0.0034	CcSEcCtD
Pomalidomide—Pneumonia—Irinotecan—colon cancer	0.00054	0.00339	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000536	0.00337	CcSEcCtD
Pomalidomide—Renal failure—Irinotecan—colon cancer	0.000528	0.00332	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Methotrexate—colon cancer	0.000526	0.0033	CcSEcCtD
Pomalidomide—Pneumonia—Fluorouracil—colon cancer	0.000517	0.00325	CcSEcCtD
Pomalidomide—Infestation NOS—Fluorouracil—colon cancer	0.000514	0.00323	CcSEcCtD
Pomalidomide—Infestation—Fluorouracil—colon cancer	0.000514	0.00323	CcSEcCtD
Pomalidomide—PTGS2—bone marrow—colon cancer	0.000505	0.0127	CbGeAlD
Pomalidomide—Neuropathy peripheral—Fluorouracil—colon cancer	0.000504	0.00317	CcSEcCtD
Pomalidomide—Urinary tract infection—Fluorouracil—colon cancer	0.0005	0.00314	CcSEcCtD
Pomalidomide—CYP1A2—liver—colon cancer	0.000493	0.0124	CbGeAlD
Pomalidomide—Atrial fibrillation—Capecitabine—colon cancer	0.000492	0.00309	CcSEcCtD
Pomalidomide—Urinary tract disorder—Vincristine—colon cancer	0.000489	0.00307	CcSEcCtD
Pomalidomide—Connective tissue disorder—Vincristine—colon cancer	0.000486	0.00306	CcSEcCtD
Pomalidomide—Urethral disorder—Vincristine—colon cancer	0.000485	0.00305	CcSEcCtD
Pomalidomide—Epistaxis—Fluorouracil—colon cancer	0.000485	0.00305	CcSEcCtD
Pomalidomide—PTGS2—vagina—colon cancer	0.000484	0.0121	CbGeAlD
Pomalidomide—CYP3A4—digestive system—colon cancer	0.000479	0.012	CbGeAlD
Pomalidomide—Pulmonary embolism—Methotrexate—colon cancer	0.000478	0.003	CcSEcCtD
Pomalidomide—Connective tissue disorder—Irinotecan—colon cancer	0.000474	0.00298	CcSEcCtD
Pomalidomide—Hyponatraemia—Capecitabine—colon cancer	0.000468	0.00294	CcSEcCtD
Pomalidomide—Pain in extremity—Capecitabine—colon cancer	0.000466	0.00293	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Methotrexate—colon cancer	0.000462	0.0029	CcSEcCtD
Pomalidomide—Cardiac disorder—Vincristine—colon cancer	0.000459	0.00289	CcSEcCtD
Pomalidomide—Angiopathy—Vincristine—colon cancer	0.000449	0.00282	CcSEcCtD
Pomalidomide—Cardiac disorder—Irinotecan—colon cancer	0.000447	0.00281	CcSEcCtD
Pomalidomide—Mediastinal disorder—Vincristine—colon cancer	0.000446	0.0028	CcSEcCtD
Pomalidomide—ABCB1—epithelium—colon cancer	0.000445	0.0112	CbGeAlD
Pomalidomide—Urinary retention—Capecitabine—colon cancer	0.000443	0.00279	CcSEcCtD
Pomalidomide—Angiopathy—Irinotecan—colon cancer	0.000437	0.00275	CcSEcCtD
Pomalidomide—Blood creatinine increased—Capecitabine—colon cancer	0.000437	0.00274	CcSEcCtD
Pomalidomide—Mediastinal disorder—Irinotecan—colon cancer	0.000434	0.00273	CcSEcCtD
Pomalidomide—Dehydration—Capecitabine—colon cancer	0.000434	0.00272	CcSEcCtD
Pomalidomide—Mental disorder—Vincristine—colon cancer	0.000434	0.00272	CcSEcCtD
Pomalidomide—Chills—Irinotecan—colon cancer	0.000433	0.00272	CcSEcCtD
Pomalidomide—Dry skin—Capecitabine—colon cancer	0.000427	0.00269	CcSEcCtD
Pomalidomide—Hypokalaemia—Capecitabine—colon cancer	0.000424	0.00267	CcSEcCtD
Pomalidomide—Breast disorder—Capecitabine—colon cancer	0.000421	0.00265	CcSEcCtD
Pomalidomide—Nasopharyngitis—Capecitabine—colon cancer	0.000417	0.00262	CcSEcCtD
Pomalidomide—Back pain—Vincristine—colon cancer	0.000417	0.00262	CcSEcCtD
Pomalidomide—Sepsis—Methotrexate—colon cancer	0.000415	0.00261	CcSEcCtD
Pomalidomide—ABCB1—renal system—colon cancer	0.000413	0.0104	CbGeAlD
Pomalidomide—Muscular weakness—Capecitabine—colon cancer	0.000411	0.00258	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000411	0.00258	CcSEcCtD
Pomalidomide—PTGS2—liver—colon cancer	0.000408	0.0102	CbGeAlD
Pomalidomide—Back pain—Irinotecan—colon cancer	0.000406	0.00255	CcSEcCtD
Pomalidomide—Muscle spasms—Irinotecan—colon cancer	0.000403	0.00253	CcSEcCtD
Pomalidomide—Anaemia—Vincristine—colon cancer	0.000398	0.0025	CcSEcCtD
Pomalidomide—Anaemia—Irinotecan—colon cancer	0.000388	0.00244	CcSEcCtD
Pomalidomide—Bronchitis—Capecitabine—colon cancer	0.000388	0.00244	CcSEcCtD
Pomalidomide—Vertigo—Vincristine—colon cancer	0.000387	0.00243	CcSEcCtD
Pomalidomide—Leukopenia—Vincristine—colon cancer	0.000386	0.00242	CcSEcCtD
Pomalidomide—Pancytopenia—Capecitabine—colon cancer	0.000383	0.0024	CcSEcCtD
Pomalidomide—Vertigo—Irinotecan—colon cancer	0.000377	0.00237	CcSEcCtD
Pomalidomide—Neutropenia—Capecitabine—colon cancer	0.000377	0.00237	CcSEcCtD
Pomalidomide—Leukopenia—Irinotecan—colon cancer	0.000376	0.00236	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Capecitabine—colon cancer	0.000375	0.00235	CcSEcCtD
Pomalidomide—Anaemia—Fluorouracil—colon cancer	0.000371	0.00233	CcSEcCtD
Pomalidomide—Weight increased—Capecitabine—colon cancer	0.000367	0.0023	CcSEcCtD
Pomalidomide—Cough—Irinotecan—colon cancer	0.000366	0.0023	CcSEcCtD
Pomalidomide—Weight decreased—Capecitabine—colon cancer	0.000365	0.00229	CcSEcCtD
Pomalidomide—Hyperglycaemia—Capecitabine—colon cancer	0.000364	0.00228	CcSEcCtD
Pomalidomide—Pneumonia—Capecitabine—colon cancer	0.000362	0.00227	CcSEcCtD
Pomalidomide—Leukopenia—Fluorouracil—colon cancer	0.00036	0.00226	CcSEcCtD
Pomalidomide—Infestation—Capecitabine—colon cancer	0.000359	0.00226	CcSEcCtD
Pomalidomide—Infestation NOS—Capecitabine—colon cancer	0.000359	0.00226	CcSEcCtD
Pomalidomide—CYP3A4—liver—colon cancer	0.000357	0.00895	CbGeAlD
Pomalidomide—Renal failure—Capecitabine—colon cancer	0.000353	0.00222	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Capecitabine—colon cancer	0.000352	0.00221	CcSEcCtD
Pomalidomide—Infection—Vincristine—colon cancer	0.000349	0.00219	CcSEcCtD
Pomalidomide—Urinary tract infection—Capecitabine—colon cancer	0.000349	0.00219	CcSEcCtD
Pomalidomide—Confusional state—Irinotecan—colon cancer	0.000345	0.00217	CcSEcCtD
Pomalidomide—Nervous system disorder—Vincristine—colon cancer	0.000345	0.00217	CcSEcCtD
Pomalidomide—Thrombocytopenia—Vincristine—colon cancer	0.000344	0.00216	CcSEcCtD
Pomalidomide—ABCB1—lymphoid tissue—colon cancer	0.000343	0.00861	CbGeAlD
Pomalidomide—Infection—Irinotecan—colon cancer	0.00034	0.00214	CcSEcCtD
Pomalidomide—Hyperhidrosis—Vincristine—colon cancer	0.00034	0.00214	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Capecitabine—colon cancer	0.00034	0.00214	CcSEcCtD
Pomalidomide—Epistaxis—Capecitabine—colon cancer	0.000339	0.00213	CcSEcCtD
Pomalidomide—ABCB1—digestive system—colon cancer	0.000339	0.00851	CbGeAlD
Pomalidomide—Nervous system disorder—Irinotecan—colon cancer	0.000336	0.00211	CcSEcCtD
Pomalidomide—Thrombocytopenia—Irinotecan—colon cancer	0.000335	0.00211	CcSEcCtD
Pomalidomide—Hyperhidrosis—Irinotecan—colon cancer	0.000331	0.00208	CcSEcCtD
Pomalidomide—Confusional state—Fluorouracil—colon cancer	0.000331	0.00208	CcSEcCtD
Pomalidomide—Infection—Fluorouracil—colon cancer	0.000326	0.00205	CcSEcCtD
Pomalidomide—Nervous system disorder—Fluorouracil—colon cancer	0.000322	0.00202	CcSEcCtD
Pomalidomide—Thrombocytopenia—Fluorouracil—colon cancer	0.000321	0.00202	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Vincristine—colon cancer	0.00032	0.00201	CcSEcCtD
Pomalidomide—Urinary tract disorder—Capecitabine—colon cancer	0.000319	0.002	CcSEcCtD
Pomalidomide—Insomnia—Vincristine—colon cancer	0.000318	0.002	CcSEcCtD
Pomalidomide—Oedema peripheral—Capecitabine—colon cancer	0.000318	0.002	CcSEcCtD
Pomalidomide—Connective tissue disorder—Capecitabine—colon cancer	0.000317	0.00199	CcSEcCtD
Pomalidomide—Urethral disorder—Capecitabine—colon cancer	0.000316	0.00199	CcSEcCtD
Pomalidomide—Breast disorder—Methotrexate—colon cancer	0.000314	0.00197	CcSEcCtD
Pomalidomide—PTGS2—lymph node—colon cancer	0.000313	0.00785	CbGeAlD
Pomalidomide—ABCB1—bone marrow—colon cancer	0.000312	0.00784	CbGeAlD
Pomalidomide—Insomnia—Irinotecan—colon cancer	0.00031	0.00195	CcSEcCtD
Pomalidomide—Decreased appetite—Vincristine—colon cancer	0.000306	0.00192	CcSEcCtD
Pomalidomide—Dyspnoea—Irinotecan—colon cancer	0.000305	0.00192	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Vincristine—colon cancer	0.000304	0.00191	CcSEcCtD
Pomalidomide—Fatigue—Vincristine—colon cancer	0.000303	0.0019	CcSEcCtD
Pomalidomide—Pain—Vincristine—colon cancer	0.000301	0.00189	CcSEcCtD
Pomalidomide—Constipation—Vincristine—colon cancer	0.000301	0.00189	CcSEcCtD
Pomalidomide—Cardiac disorder—Capecitabine—colon cancer	0.000299	0.00188	CcSEcCtD
Pomalidomide—ABCB1—vagina—colon cancer	0.000299	0.00751	CbGeAlD
Pomalidomide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000299	0.00188	CcSEcCtD
Pomalidomide—Decreased appetite—Irinotecan—colon cancer	0.000298	0.00187	CcSEcCtD
Pomalidomide—Insomnia—Fluorouracil—colon cancer	0.000297	0.00186	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Irinotecan—colon cancer	0.000296	0.00186	CcSEcCtD
Pomalidomide—Fatigue—Irinotecan—colon cancer	0.000295	0.00185	CcSEcCtD
Pomalidomide—Constipation—Irinotecan—colon cancer	0.000293	0.00184	CcSEcCtD
Pomalidomide—Pain—Irinotecan—colon cancer	0.000293	0.00184	CcSEcCtD
Pomalidomide—Angiopathy—Capecitabine—colon cancer	0.000293	0.00184	CcSEcCtD
Pomalidomide—Dyspnoea—Fluorouracil—colon cancer	0.000292	0.00184	CcSEcCtD
Pomalidomide—Mediastinal disorder—Capecitabine—colon cancer	0.000291	0.00183	CcSEcCtD
Pomalidomide—Chills—Capecitabine—colon cancer	0.00029	0.00182	CcSEcCtD
Pomalidomide—Decreased appetite—Fluorouracil—colon cancer	0.000285	0.00179	CcSEcCtD
Pomalidomide—Pancytopenia—Methotrexate—colon cancer	0.000285	0.00179	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000283	0.00178	CcSEcCtD
Pomalidomide—Mental disorder—Capecitabine—colon cancer	0.000283	0.00178	CcSEcCtD
Pomalidomide—Feeling abnormal—Irinotecan—colon cancer	0.000282	0.00177	CcSEcCtD
Pomalidomide—Malnutrition—Capecitabine—colon cancer	0.000281	0.00176	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—colon cancer	0.000281	0.00176	CcSEcCtD
Pomalidomide—Pain—Fluorouracil—colon cancer	0.000281	0.00176	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Methotrexate—colon cancer	0.000279	0.00175	CcSEcCtD
Pomalidomide—Body temperature increased—Vincristine—colon cancer	0.000278	0.00175	CcSEcCtD
Pomalidomide—Back pain—Capecitabine—colon cancer	0.000272	0.00171	CcSEcCtD
Pomalidomide—Body temperature increased—Irinotecan—colon cancer	0.000271	0.0017	CcSEcCtD
Pomalidomide—Feeling abnormal—Fluorouracil—colon cancer	0.00027	0.0017	CcSEcCtD
Pomalidomide—Muscle spasms—Capecitabine—colon cancer	0.00027	0.0017	CcSEcCtD
Pomalidomide—Pneumonia—Methotrexate—colon cancer	0.000269	0.00169	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—colon cancer	0.000268	0.00168	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—colon cancer	0.000268	0.00168	CcSEcCtD
Pomalidomide—Tremor—Capecitabine—colon cancer	0.000263	0.00165	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—colon cancer	0.000263	0.00165	CcSEcCtD
Pomalidomide—Anaemia—Capecitabine—colon cancer	0.00026	0.00163	CcSEcCtD
Pomalidomide—Body temperature increased—Fluorouracil—colon cancer	0.000259	0.00163	CcSEcCtD
Pomalidomide—Hypersensitivity—Vincristine—colon cancer	0.000259	0.00163	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—colon cancer	0.000253	0.00159	CcSEcCtD
Pomalidomide—ABCB1—liver—colon cancer	0.000252	0.00634	CbGeAlD
Pomalidomide—Epistaxis—Methotrexate—colon cancer	0.000252	0.00159	CcSEcCtD
Pomalidomide—Vertigo—Capecitabine—colon cancer	0.000252	0.00159	CcSEcCtD
Pomalidomide—Hypersensitivity—Irinotecan—colon cancer	0.000252	0.00159	CcSEcCtD
Pomalidomide—Asthenia—Vincristine—colon cancer	0.000252	0.00158	CcSEcCtD
Pomalidomide—Leukopenia—Capecitabine—colon cancer	0.000251	0.00158	CcSEcCtD
Pomalidomide—Asthenia—Irinotecan—colon cancer	0.000246	0.00154	CcSEcCtD
Pomalidomide—Cough—Capecitabine—colon cancer	0.000245	0.00154	CcSEcCtD
Pomalidomide—Hypersensitivity—Fluorouracil—colon cancer	0.000242	0.00152	CcSEcCtD
Pomalidomide—Diarrhoea—Vincristine—colon cancer	0.000241	0.00151	CcSEcCtD
Pomalidomide—Arthralgia—Capecitabine—colon cancer	0.000239	0.0015	CcSEcCtD
Pomalidomide—Anxiety—Capecitabine—colon cancer	0.000238	0.0015	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000237	0.00149	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—colon cancer	0.000237	0.00149	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—colon cancer	0.000235	0.00148	CcSEcCtD
Pomalidomide—Diarrhoea—Irinotecan—colon cancer	0.000234	0.00147	CcSEcCtD
Pomalidomide—Dizziness—Vincristine—colon cancer	0.000233	0.00146	CcSEcCtD
Pomalidomide—Pruritus—Fluorouracil—colon cancer	0.000232	0.00146	CcSEcCtD
Pomalidomide—Confusional state—Capecitabine—colon cancer	0.000231	0.00145	CcSEcCtD
Pomalidomide—Infection—Capecitabine—colon cancer	0.000228	0.00143	CcSEcCtD
Pomalidomide—Dizziness—Irinotecan—colon cancer	0.000226	0.00142	CcSEcCtD
Pomalidomide—Nervous system disorder—Capecitabine—colon cancer	0.000225	0.00141	CcSEcCtD
Pomalidomide—Diarrhoea—Fluorouracil—colon cancer	0.000224	0.00141	CcSEcCtD
Pomalidomide—Thrombocytopenia—Capecitabine—colon cancer	0.000224	0.00141	CcSEcCtD
Pomalidomide—Vomiting—Vincristine—colon cancer	0.000224	0.0014	CcSEcCtD
Pomalidomide—Cardiac disorder—Methotrexate—colon cancer	0.000223	0.0014	CcSEcCtD
Pomalidomide—Skin disorder—Capecitabine—colon cancer	0.000223	0.0014	CcSEcCtD
Pomalidomide—Rash—Vincristine—colon cancer	0.000222	0.00139	CcSEcCtD
Pomalidomide—Hyperhidrosis—Capecitabine—colon cancer	0.000222	0.00139	CcSEcCtD
Pomalidomide—Dermatitis—Vincristine—colon cancer	0.000222	0.00139	CcSEcCtD
Pomalidomide—Headache—Vincristine—colon cancer	0.00022	0.00138	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—colon cancer	0.000218	0.00137	CcSEcCtD
Pomalidomide—Vomiting—Irinotecan—colon cancer	0.000218	0.00137	CcSEcCtD
Pomalidomide—Dizziness—Fluorouracil—colon cancer	0.000217	0.00136	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—colon cancer	0.000216	0.00136	CcSEcCtD
Pomalidomide—Rash—Irinotecan—colon cancer	0.000216	0.00136	CcSEcCtD
Pomalidomide—Dermatitis—Irinotecan—colon cancer	0.000216	0.00136	CcSEcCtD
Pomalidomide—Chills—Methotrexate—colon cancer	0.000216	0.00135	CcSEcCtD
Pomalidomide—Headache—Irinotecan—colon cancer	0.000215	0.00135	CcSEcCtD
Pomalidomide—Mental disorder—Methotrexate—colon cancer	0.00021	0.00132	CcSEcCtD
Pomalidomide—Malnutrition—Methotrexate—colon cancer	0.000209	0.00131	CcSEcCtD
Pomalidomide—Nausea—Vincristine—colon cancer	0.000209	0.00131	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000209	0.00131	CcSEcCtD
Pomalidomide—Vomiting—Fluorouracil—colon cancer	0.000209	0.00131	CcSEcCtD
Pomalidomide—Insomnia—Capecitabine—colon cancer	0.000207	0.0013	CcSEcCtD
Pomalidomide—Rash—Fluorouracil—colon cancer	0.000207	0.0013	CcSEcCtD
Pomalidomide—Dermatitis—Fluorouracil—colon cancer	0.000207	0.0013	CcSEcCtD
Pomalidomide—Headache—Fluorouracil—colon cancer	0.000205	0.00129	CcSEcCtD
Pomalidomide—Dyspnoea—Capecitabine—colon cancer	0.000204	0.00128	CcSEcCtD
Pomalidomide—Nausea—Irinotecan—colon cancer	0.000203	0.00128	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—colon cancer	0.000202	0.00127	CcSEcCtD
Pomalidomide—Decreased appetite—Capecitabine—colon cancer	0.000199	0.00125	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Capecitabine—colon cancer	0.000198	0.00124	CcSEcCtD
Pomalidomide—Fatigue—Capecitabine—colon cancer	0.000198	0.00124	CcSEcCtD
Pomalidomide—Pain—Capecitabine—colon cancer	0.000196	0.00123	CcSEcCtD
Pomalidomide—Constipation—Capecitabine—colon cancer	0.000196	0.00123	CcSEcCtD
Pomalidomide—Nausea—Fluorouracil—colon cancer	0.000195	0.00122	CcSEcCtD
Pomalidomide—ABCB1—lymph node—colon cancer	0.000194	0.00486	CbGeAlD
Pomalidomide—Anaemia—Methotrexate—colon cancer	0.000193	0.00121	CcSEcCtD
Pomalidomide—Feeling abnormal—Capecitabine—colon cancer	0.000189	0.00119	CcSEcCtD
Pomalidomide—Vertigo—Methotrexate—colon cancer	0.000188	0.00118	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—colon cancer	0.000187	0.00118	CcSEcCtD
Pomalidomide—Cough—Methotrexate—colon cancer	0.000182	0.00115	CcSEcCtD
Pomalidomide—Body temperature increased—Capecitabine—colon cancer	0.000181	0.00114	CcSEcCtD
Pomalidomide—Arthralgia—Methotrexate—colon cancer	0.000178	0.00112	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000177	0.00111	CcSEcCtD
Pomalidomide—Confusional state—Methotrexate—colon cancer	0.000172	0.00108	CcSEcCtD
Pomalidomide—Infection—Methotrexate—colon cancer	0.00017	0.00106	CcSEcCtD
Pomalidomide—Hypersensitivity—Capecitabine—colon cancer	0.000169	0.00106	CcSEcCtD
Pomalidomide—Nervous system disorder—Methotrexate—colon cancer	0.000167	0.00105	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—colon cancer	0.000167	0.00105	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—colon cancer	0.000166	0.00104	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—colon cancer	0.000165	0.00104	CcSEcCtD
Pomalidomide—Asthenia—Capecitabine—colon cancer	0.000164	0.00103	CcSEcCtD
Pomalidomide—Pruritus—Capecitabine—colon cancer	0.000162	0.00102	CcSEcCtD
Pomalidomide—Diarrhoea—Capecitabine—colon cancer	0.000157	0.000985	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000155	0.000977	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—colon cancer	0.000154	0.000969	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—colon cancer	0.000152	0.000956	CcSEcCtD
Pomalidomide—Dizziness—Capecitabine—colon cancer	0.000152	0.000952	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—colon cancer	0.000148	0.000932	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Methotrexate—colon cancer	0.000147	0.000925	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—colon cancer	0.000147	0.000924	CcSEcCtD
Pomalidomide—Pain—Methotrexate—colon cancer	0.000146	0.000917	CcSEcCtD
Pomalidomide—Vomiting—Capecitabine—colon cancer	0.000146	0.000915	CcSEcCtD
Pomalidomide—Rash—Capecitabine—colon cancer	0.000145	0.000908	CcSEcCtD
Pomalidomide—Dermatitis—Capecitabine—colon cancer	0.000144	0.000907	CcSEcCtD
Pomalidomide—Headache—Capecitabine—colon cancer	0.000144	0.000902	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000141	0.00367	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Methotrexate—colon cancer	0.000141	0.000883	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—NRAS—colon cancer	0.00014	0.00366	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.00014	0.00364	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—colon cancer	0.000139	0.00361	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000138	0.0036	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP3—colon cancer	0.000138	0.0036	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000137	0.00357	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—BCL2L1—colon cancer	0.000137	0.00356	CbGpPWpGaD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000136	0.00355	CbGpPWpGaD
Pomalidomide—Nausea—Capecitabine—colon cancer	0.000136	0.000855	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—colon cancer	0.000135	0.000847	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—PPARG—colon cancer	0.000133	0.00347	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000133	0.00347	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—colon cancer	0.000133	0.00347	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—EP300—colon cancer	0.000133	0.00346	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	0.00013	0.00339	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—AKT1—colon cancer	0.00013	0.00339	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—colon cancer	0.000129	0.00337	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—CASP3—colon cancer	0.000128	0.00335	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Methotrexate—colon cancer	0.000126	0.00079	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—DCC—colon cancer	0.000125	0.00327	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.000124	0.00323	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—VEGFA—colon cancer	0.000123	0.00321	CbGpPWpGaD
Pomalidomide—Asthenia—Methotrexate—colon cancer	0.000122	0.000769	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—KRAS—colon cancer	0.000121	0.00315	CbGpPWpGaD
Pomalidomide—Pruritus—Methotrexate—colon cancer	0.000121	0.000758	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—HRAS—colon cancer	0.000121	0.00314	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.00012	0.00314	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—APC—colon cancer	0.00012	0.00313	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000118	0.00306	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000117	0.00306	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—AKT1—colon cancer	0.000117	0.00305	CbGpPWpGaD
Pomalidomide—Diarrhoea—Methotrexate—colon cancer	0.000117	0.000733	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.000116	0.00302	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—colon cancer	0.000115	0.003	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—PTGS2—colon cancer	0.000113	0.00295	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—AKT1—colon cancer	0.000113	0.00295	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—TGFB1—colon cancer	0.000113	0.00294	CbGpPWpGaD
Pomalidomide—Dizziness—Methotrexate—colon cancer	0.000113	0.000709	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000112	0.00291	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CDH1—colon cancer	0.00011	0.00288	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—colon cancer	0.00011	0.00287	CbGpPWpGaD
Pomalidomide—Vomiting—Methotrexate—colon cancer	0.000108	0.000682	CcSEcCtD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—colon cancer	0.000108	0.00282	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.000108	0.00281	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—MYC—colon cancer	0.000108	0.00281	CbGpPWpGaD
Pomalidomide—Rash—Methotrexate—colon cancer	0.000108	0.000676	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—NRAS—colon cancer	0.000108	0.0028	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—colon cancer	0.000108	0.0028	CbGpPWpGaD
Pomalidomide—Dermatitis—Methotrexate—colon cancer	0.000107	0.000675	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—TP53—colon cancer	0.000107	0.0028	CbGpPWpGaD
Pomalidomide—Headache—Methotrexate—colon cancer	0.000107	0.000671	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—BRAF—colon cancer	0.000106	0.00276	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000106	0.00275	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HNF4A—colon cancer	0.000106	0.00275	CbGpPWpGaD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000105	0.00274	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CASP3—colon cancer	0.000105	0.00274	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—AKT1—colon cancer	0.000105	0.00273	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HRAS—colon cancer	0.000103	0.00268	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CCND1—colon cancer	0.000102	0.00267	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—AKT1—colon cancer	0.000102	0.00266	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000102	0.00265	CbGpPWpGaD
Pomalidomide—Nausea—Methotrexate—colon cancer	0.000101	0.000637	CcSEcCtD
Pomalidomide—PTGS2—Metabolism—CA7—colon cancer	0.000101	0.00264	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	9.97e-05	0.0026	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	9.89e-05	0.00258	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CTNNB1—colon cancer	9.38e-05	0.00245	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—colon cancer	9.3e-05	0.00242	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—KRAS—colon cancer	9.26e-05	0.00241	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—CDKN1A—colon cancer	9.17e-05	0.00239	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—PIK3CA—colon cancer	9.15e-05	0.00238	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—colon cancer	8.85e-05	0.00231	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	8.71e-05	0.00227	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	8.55e-05	0.00223	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	8.48e-05	0.00221	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CASP3—colon cancer	8.46e-05	0.0022	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	8.43e-05	0.0022	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CASP3—colon cancer	8.41e-05	0.00219	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CCND1—colon cancer	8.31e-05	0.00217	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	8.24e-05	0.00215	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MYC—colon cancer	8.21e-05	0.00214	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TGFB1—colon cancer	8.19e-05	0.00213	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—CTNNB1—colon cancer	8.15e-05	0.00212	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—CTNNB1—colon cancer	8.11e-05	0.00211	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN1A—colon cancer	8.04e-05	0.0021	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—EGFR—colon cancer	8.03e-05	0.00209	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—CASP3—colon cancer	7.93e-05	0.00207	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	7.91e-05	0.00206	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—colon cancer	7.88e-05	0.00205	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—HRAS—colon cancer	7.87e-05	0.00205	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—PIK3CA—colon cancer	7.83e-05	0.00204	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	7.71e-05	0.00201	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—EP300—colon cancer	7.65e-05	0.00199	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—TGFB1—colon cancer	7.58e-05	0.00198	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—EP300—colon cancer	7.54e-05	0.00196	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AKT1—colon cancer	7.47e-05	0.00195	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—colon cancer	7.47e-05	0.00195	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	7.36e-05	0.00192	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LGR5—colon cancer	7.32e-05	0.00191	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CHST5—colon cancer	7.32e-05	0.00191	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	7.27e-05	0.0019	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CA7—colon cancer	7.17e-05	0.00187	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—NRAS—colon cancer	7.16e-05	0.00186	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	7.16e-05	0.00186	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—colon cancer	7.14e-05	0.00186	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	7.01e-05	0.00183	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—colon cancer	7.01e-05	0.00183	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	6.96e-05	0.00182	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—AKT1—colon cancer	6.95e-05	0.00181	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	6.9e-05	0.0018	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	6.81e-05	0.00178	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—colon cancer	6.81e-05	0.00178	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—colon cancer	6.74e-05	0.00176	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	6.74e-05	0.00176	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYC—colon cancer	6.67e-05	0.00174	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—NRAS—colon cancer	6.65e-05	0.00173	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	6.64e-05	0.00173	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	6.58e-05	0.00171	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	6.56e-05	0.00171	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CASP3—colon cancer	6.51e-05	0.0017	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	6.41e-05	0.00167	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—AKT1—colon cancer	6.4e-05	0.00167	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—CASP3—colon cancer	6.36e-05	0.00166	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCND1—colon cancer	6.33e-05	0.00165	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—colon cancer	6.28e-05	0.00164	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	6.23e-05	0.00162	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	6.23e-05	0.00162	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—colon cancer	6.19e-05	0.00161	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFB1—colon cancer	6.18e-05	0.00161	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—KRAS—colon cancer	6.16e-05	0.00161	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ODC1—colon cancer	6.13e-05	0.0016	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CHST5—colon cancer	6.13e-05	0.0016	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—PIK3CA—colon cancer	6.12e-05	0.00159	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	6.11e-05	0.00159	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	6.09e-05	0.00159	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	6.07e-05	0.00158	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	6.06e-05	0.00158	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—colon cancer	6.05e-05	0.00158	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	5.97e-05	0.00156	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	5.97e-05	0.00156	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	5.84e-05	0.00152	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CA7—colon cancer	5.73e-05	0.00149	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—KRAS—colon cancer	5.72e-05	0.00149	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	5.64e-05	0.00147	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	5.59e-05	0.00146	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	5.57e-05	0.00145	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	5.46e-05	0.00142	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—colon cancer	5.42e-05	0.00141	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—colon cancer	5.39e-05	0.00141	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AXIN2—colon cancer	5.26e-05	0.00137	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—HRAS—colon cancer	5.24e-05	0.00136	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	5.16e-05	0.00135	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—colon cancer	5.08e-05	0.00132	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—colon cancer	5.08e-05	0.00132	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TGFB1—colon cancer	5.07e-05	0.00132	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—colon cancer	5e-05	0.0013	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—colon cancer	4.97e-05	0.00129	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TGFB1—colon cancer	4.95e-05	0.00129	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	4.8e-05	0.00125	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	4.74e-05	0.00124	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	4.59e-05	0.0012	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PPARG—colon cancer	4.58e-05	0.00119	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—colon cancer	4.58e-05	0.00119	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	4.45e-05	0.00116	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	4.43e-05	0.00115	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CA7—colon cancer	4.42e-05	0.00115	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CHST5—colon cancer	4.35e-05	0.00113	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ODC1—colon cancer	4.35e-05	0.00113	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	4.31e-05	0.00112	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—AKT1—colon cancer	4.29e-05	0.00112	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	4.27e-05	0.00111	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—colon cancer	4.17e-05	0.00109	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	4.17e-05	0.00109	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	3.97e-05	0.00104	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	3.96e-05	0.00103	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	3.87e-05	0.00101	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	3.86e-05	0.001	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	3.76e-05	0.000979	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ODC1—colon cancer	3.47e-05	0.000904	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CHST5—colon cancer	3.47e-05	0.000904	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	3.45e-05	0.0009	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	3.45e-05	0.000898	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	3.38e-05	0.000881	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	3.38e-05	0.000881	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CTNNB1—colon cancer	3.22e-05	0.00084	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	3.19e-05	0.000832	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	3.14e-05	0.000817	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	3.05e-05	0.000796	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	3.02e-05	0.000788	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EP300—colon cancer	3e-05	0.000781	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.95e-05	0.00077	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	2.93e-05	0.000764	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—SRC—colon cancer	2.91e-05	0.00076	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—colon cancer	2.84e-05	0.00074	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.84e-05	0.000739	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	2.81e-05	0.000732	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NRAS—colon cancer	2.8e-05	0.000731	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	2.73e-05	0.000712	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ODC1—colon cancer	2.68e-05	0.000698	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CHST5—colon cancer	2.68e-05	0.000698	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	2.66e-05	0.000694	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TGFB1—colon cancer	2.61e-05	0.000679	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—colon cancer	2.55e-05	0.000666	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.53e-05	0.000659	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	2.45e-05	0.000638	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	2.44e-05	0.000637	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KRAS—colon cancer	2.41e-05	0.000629	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.4e-05	0.000624	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	2.4e-05	0.000624	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	2.26e-05	0.00059	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	2.08e-05	0.000542	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—colon cancer	2.05e-05	0.000535	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.01e-05	0.000524	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—colon cancer	1.81e-05	0.000472	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.7e-05	0.000443	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.66e-05	0.000431	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ABCB1—colon cancer	1.62e-05	0.000422	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TYMS—colon cancer	1.59e-05	0.000415	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGFR3—colon cancer	1.52e-05	0.000396	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.43e-05	0.000373	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APC—colon cancer	1.39e-05	0.000363	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BRAF—colon cancer	1.31e-05	0.000342	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.22e-05	0.000319	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TYMS—colon cancer	1.13e-05	0.000294	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARG—colon cancer	1.13e-05	0.000294	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.13e-05	0.000294	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—colon cancer	9.47e-06	0.000247	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.37e-06	0.000244	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1A—colon cancer	9.25e-06	0.000241	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCB1—colon cancer	9.17e-06	0.000239	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TYMS—colon cancer	9e-06	0.000235	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EP300—colon cancer	8.8e-06	0.000229	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SRC—colon cancer	8.56e-06	0.000223	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NRAS—colon cancer	8.24e-06	0.000215	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARG—colon cancer	7.99e-06	0.000208	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—colon cancer	7.67e-06	0.0002	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—colon cancer	7.65e-06	0.000199	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—colon cancer	7.5e-06	0.000196	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—EP300—colon cancer	7.37e-06	0.000192	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KRAS—colon cancer	7.09e-06	0.000185	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCB1—colon cancer	7.07e-06	0.000184	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TYMS—colon cancer	6.95e-06	0.000181	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.93e-06	0.000181	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CA—colon cancer	6.51e-06	0.00017	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARG—colon cancer	6.38e-06	0.000166	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—colon cancer	6.28e-06	0.000164	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—colon cancer	6.03e-06	0.000157	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CA—colon cancer	5.45e-06	0.000142	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—colon cancer	5.32e-06	0.000139	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—EP300—colon cancer	5.23e-06	0.000136	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—colon cancer	5.02e-06	0.000131	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARG—colon cancer	4.92e-06	0.000128	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—colon cancer	4.46e-06	0.000116	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—EP300—colon cancer	4.17e-06	0.000109	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—colon cancer	3.87e-06	0.000101	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CA—colon cancer	3.87e-06	0.000101	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—EP300—colon cancer	3.22e-06	8.39e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—colon cancer	3.16e-06	8.23e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CA—colon cancer	3.09e-06	8.04e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—colon cancer	2.52e-06	6.57e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CA—colon cancer	2.38e-06	6.21e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—colon cancer	1.95e-06	5.07e-05	CbGpPWpGaD
